Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression. Issue 4 (13th March 2019)

• Record Type: Journal Article
• Authors: Schaff, Lauren R.; Marghoob, Ashfaq; Rosenblum, Marc K.; Meyer, Rina; Khakoo, Yasmin
• Is Part Of: Pediatric dermatology. Volume 36:Issue 4(2019)
• Page Start: 497
• Page End: 500
• Publication Date: 2019-03-13
• Subjects: immunodeficiency -- neoplasms‐malignant -- melanocytic nevi -- TNF inhibitor; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.13804
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16‐year‐old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti‐TNF therapy for inflammatory bowel disease.